diflunisal has been researched along with Amyloid Neuropathy Type 1 in 35 studies
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we report the diflunisal plasma concentrations measured by extraction, reversed phase HPLC separation, and fluorescence detection after long-term 250 mg BID oral dosing in two groups: a placebo-controlled diflunisal clinical trial group and an open-label Japanese polyneuropathy treatment cohort." | 1.91 | Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. ( Berk, JL; Jäger, M; Kelly, JW; Kline, GM; Nelson, LT; Powers, ET; Sekijima, Y; Tsai, FJ, 2023) |
| "Diflunisal is an approved non-steroidal anti-inflammatory drug that stabilizes TTR, with limited data available regarding effects on cardiac structure and function." | 1.56 | Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. ( Berk, JL; Connors, LH; Fox, J; Gopal, DM; Hellawell, J; Lohrmann, G; Maurer, MS; Mussinelli, R; Pipilas, A; Ruberg, FL; Siddiqi, OK; Vellanki, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.71) | 29.6817 |
| 2010's | 18 (51.43) | 24.3611 |
| 2020's | 15 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoyama, T | 3 |
| Kosaka, Y | 1 |
| Mizuguchi, M | 3 |
| Connelly, S | 1 |
| Mortenson, DE | 1 |
| Choi, S | 1 |
| Wilson, IA | 1 |
| Powers, ET | 5 |
| Kelly, JW | 8 |
| Johnson, SM | 1 |
| Miller, M | 1 |
| Pal, A | 1 |
| Albusairi, W | 1 |
| Joo, H | 1 |
| Pappas, B | 1 |
| Haque Tuhin, MT | 1 |
| Liang, D | 1 |
| Jampala, R | 1 |
| Liu, F | 1 |
| Khan, J | 1 |
| Faaij, M | 1 |
| Park, M | 1 |
| Chan, W | 1 |
| Graef, I | 1 |
| Zamboni, R | 1 |
| Kumar, N | 1 |
| Fox, J | 2 |
| Sinha, U | 1 |
| Alhamadsheh, M | 1 |
| Kitakami, R | 1 |
| Inui, K | 1 |
| Nakagawa, Y | 1 |
| Sawai, Y | 1 |
| Katayama, W | 1 |
| Okada, T | 1 |
| Kanamitsu, K | 1 |
| Nakagawa, S | 1 |
| Toyooka, N | 1 |
| Kashihara, M | 1 |
| Villanueva, E | 1 |
| Carretero, M | 1 |
| Aguirre, MA | 1 |
| Negro, A | 1 |
| Belziti, CA | 1 |
| Posadas-Martínez, ML | 1 |
| Nucifora, EM | 1 |
| Baratta, S | 1 |
| Costabel, JP | 1 |
| Higa, C | 1 |
| Rivas, C | 1 |
| Fernández, A | 1 |
| Quiroga, A | 1 |
| Dumont, CA | 1 |
| Volberg, VI | 1 |
| Streitenberg, GM | 1 |
| Perez de Arenaza, D | 1 |
| Tsai, FJ | 3 |
| Nelson, LT | 4 |
| Kline, GM | 3 |
| Jäger, M | 3 |
| Berk, JL | 7 |
| Sekijima, Y | 11 |
| Nuvolone, M | 1 |
| Girelli, M | 1 |
| Merlini, G | 3 |
| Lohrmann, G | 1 |
| Pipilas, A | 1 |
| Mussinelli, R | 1 |
| Gopal, DM | 1 |
| Connors, LH | 2 |
| Vellanki, N | 1 |
| Hellawell, J | 1 |
| Siddiqi, OK | 2 |
| Maurer, MS | 3 |
| Ruberg, FL | 1 |
| Rubin, J | 1 |
| Magrinelli, F | 1 |
| Fabrizi, GM | 1 |
| Santoro, L | 1 |
| Manganelli, F | 1 |
| Zanette, G | 1 |
| Cavallaro, T | 1 |
| Tamburin, S | 1 |
| Lin, H | 1 |
| Merkel, M | 1 |
| Hale, C | 1 |
| Marantz, JL | 1 |
| Cristóbal Gutiérrez, H | 1 |
| Pelayo-Negro, AL | 1 |
| Gómez Gómez, D | 1 |
| Martín Vega, MÁ | 1 |
| Valero Domínguez, M | 1 |
| Paxman, RJ | 1 |
| Xu, J | 1 |
| Webb, B | 1 |
| Benbrahim, M | 1 |
| Norman, K | 1 |
| Sanchorawala, V | 1 |
| Hughes, D | 1 |
| Patel, RK | 1 |
| Fontana, M | 1 |
| Hawkins, PN | 1 |
| Gillmore, J | 1 |
| Ibrahim, M | 1 |
| Saint Croix, GR | 1 |
| Lacy, S | 1 |
| Fattouh, M | 1 |
| Barillas-Lara, MI | 1 |
| Behrooz, L | 1 |
| Mechanic, O | 1 |
| Koike, H | 1 |
| Katsuno, M | 1 |
| Azorín, SE | 1 |
| Cabib, CE | 1 |
| Campistol, JM | 1 |
| Klimtchuk, ES | 1 |
| Prokaeva, T | 1 |
| Frame, NM | 1 |
| Abdullahi, HA | 1 |
| Spencer, B | 1 |
| Dasari, S | 1 |
| Cui, H | 1 |
| Kurtin, PJ | 1 |
| Gursky, O | 1 |
| Buxbaum, JN | 1 |
| Adams, D | 2 |
| Cauquil, C | 2 |
| Théaudin, M | 2 |
| Suhr, OB | 2 |
| Obici, L | 2 |
| Zeldenrust, SR | 2 |
| Yamashita, T | 2 |
| Heneghan, MA | 1 |
| Gorevic, PD | 1 |
| Litchy, WJ | 1 |
| Wiesman, JF | 1 |
| Nordh, E | 1 |
| Corato, M | 1 |
| Lozza, A | 1 |
| Cortese, A | 1 |
| Robinson-Papp, J | 1 |
| Colton, T | 1 |
| Rybin, DV | 1 |
| Bisbee, AB | 2 |
| Ando, Y | 2 |
| Ikeda, S | 4 |
| Seldin, DC | 1 |
| Skinner, M | 2 |
| Dyck, PJ | 2 |
| Takahashi, R | 1 |
| Ono, K | 1 |
| Shibata, S | 1 |
| Nakamura, K | 1 |
| Komatsu, J | 1 |
| Ikeda, Y | 1 |
| Ikeda, T | 1 |
| Samuraki, M | 1 |
| Sakai, K | 1 |
| Iwasa, K | 1 |
| Kayano, D | 1 |
| Yamada, M | 1 |
| Vilaró, M | 1 |
| Nieto, J | 1 |
| La Parra, JR | 1 |
| Almeida, MR | 1 |
| Ballesteros, A | 1 |
| Planas, A | 1 |
| Arsequell, G | 1 |
| Valencia, G | 1 |
| Castaño, A | 1 |
| Drachman, BM | 1 |
| Judge, D | 1 |
| Labeyrie, C | 1 |
| Beaudonnet, G | 1 |
| Algalarrondo, V | 1 |
| Heneghan, M | 1 |
| Gorevic, P | 1 |
| Tojo, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis[NCT06034405] | 1,663 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| The Effect of Diflunisal on Familial Amyloidosis[NCT00294671] | Phase 2/Phase 3 | 130 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline of the Kumamoto Score (0-102 points, increasing with disease severity), a clinical neurologic scale of motor, sensory, and autonomic function combined with heart and kidney end organ measures developed to track disease progression in Familial Amyloid Polyneuropathy (ATTR-FAP) (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 3.1 | 1.9 |
| Placebo | 8.0 | 4.1 |
The product of body mass index (BMI) and serum albumin level (g/L) [kg/M2xg/L]. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | kg/M2xg/L (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | -33.7 | -18.7 |
| Placebo | -67.9 | -38.5 |
The primary endpoint, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurologic deficits) to 270 points (no detectable peripheral nerve function). (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 8.2 | 6.2 |
| Placebo | 26.3 | 12.5 |
The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of mental component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 3.5 | 2.5 |
| Placebo | -0.9 | 0.8 |
The 36 item short-form health survey (SF-36) was used to assess the difference between treatment groups for change of physical component scores over 2 years treatment. Range 0-100; lower scores reflect lower quality-of-life. (NCT00294671)
Timeframe: Baseline, 1 and 2 years
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change from baseline to 2 years | Change from baseline to 1 year | |
| Diflunisal | 1.2 | 0.7 |
| Placebo | -4.9 | -1.9 |
15 reviews available for diflunisal and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
Topics: Amyloid; Amyloid Neuropathies, Familial; Cardiomyopathies; Diflunisal; Humans; Prealbumin | 2022 |
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Arrhythmias, Cardiac; Benzoates; Benzoxazoles; Biopsy; | 2020 |
Pharmacological treatment for familial amyloid polyneuropathy.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Disease Progression; Humans; Oligonucleoti | 2020 |
Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Liver Transplantation; RNA, Small | 2020 |
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Cardiomyopathies; Cardiovascular Agents; Difl | 2021 |
The use of diflunisal for transthyretin cardiac amyloidosis: a review.
Topics: Adult; Amyloid Neuropathies, Familial; Diflunisal; Humans; Myocardium; Prealbumin | 2022 |
The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Topics: Alzheimer Disease; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Immuno | 2021 |
Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Topics: Amyloid Neuropathies; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Female; Humans; Male | 2019 |
[Familial amyloid polyneuropathies: therapeutic issues].
Topics: Amyloid Neuropathies, Familial; Antibodies, Monoclonal; Benzoxazoles; Clinical Trials as Topic; Difl | 2012 |
Recent progress in the understanding and treatment of transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Genetic Therapy; Humans; Liver Transplanta | 2014 |
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Cardiomyopathies; Cyclooxygenase Inhibitor | 2015 |
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Mutation; Prealbumin | 2015 |
[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amyloid; Amyloid Neuropathies, Familial; Benzoxazoles; | 2014 |
TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Clinical Trials, Phase III as Topic; Diflunisal; Disea | 2016 |
[Therapeutic strategy for familial amyloid polyneuropathy (FAP)].
Topics: Amino Acid Substitution; Amyloid; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Ster | 2009 |
3 trials available for diflunisal and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Female; Humans; Male; Middle | 2020 |
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
Topics: Aged; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Difl | 2013 |
The Diflunisal Trial: study accrual and drug tolerance.
Topics: Adult; Aged; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Diflunisal; Fe | 2012 |
17 other studies available for diflunisal and Amyloid Neuropathy Type 1
| Article | Year |
|---|---|
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Caffeic Acids; Coumaric Acids; Masoprocol; Phenylethyl | 2014 |
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Topics: Amyloid Neuropathies, Familial; Computer Simulation; Drug Design; Humans; Molecular Docking Simulati | 2017 |
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.
Topics: Administration, Oral; Amyloid Neuropathies, Familial; Animals; Benzoates; Biomimetics; Dogs; Entropy | 2018 |
Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
Topics: Amyloid Neuropathies, Familial; Anthraquinones; Crystallography, X-Ray; Dose-Response Relationship, | 2021 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning | 2021 |
[Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Diflunisal; Doxycycline; Humans; Pre | 2022 |
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Topics: Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Diflunisal; Excipients; Hum | 2023 |
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Topics: Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Diflunisal; Excipients; Hum | 2023 |
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Topics: Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Diflunisal; Excipients; Hum | 2023 |
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
Topics: Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Diflunisal; Excipients; Hum | 2023 |
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Cardiomyopathies; Diflunisal; Female; Heart | 2020 |
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Topics: Amyloid; Amyloid Neuropathies, Familial; Benzoates; Benzoxazoles; Cardiomyopathies; Diflunisal; Huma | 2021 |
Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.
Topics: Amyloid Neuropathies, Familial; Diflunisal; Humans; Multimodal Imaging; Prealbumin; RNA, Small Inter | 2021 |
Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
Topics: Aged; Amyloid; Amyloid Neuropathies; Amyloid Neuropathies, Familial; Diflunisal; Female; Humans; Mal | 2017 |
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Topics: Amyloid; Amyloid Neuropathies, Familial; Diflunisal; Drug Resistance; Female; Humans; Male; Models, | 2018 |
[Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Diflunisal; Humans; Liver Transplantation; Molecular T | 2014 |
Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Topics: 3-Iodobenzylguanidine; Aged; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal | 2014 |
Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions.
Topics: Amyloid Neuropathies, Familial; Combinatorial Chemistry Techniques; Diflunisal; Humans; Structure-Ac | 2015 |
[Familial amyloid polyneuropathy: diflunisal].
Topics: Amyloid Neuropathies, Familial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To | 2010 |
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Topics: Adult; Aged; Amyloid beta-Peptides; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-St | 2006 |